Nasdaq
$36.02▼ 0.25%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $2.09BShares out 57.9M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
14- 10.13Pre-market26.10.13 21:008-KKey event#●●●#●●●
Harmony Biosciences Holdings, Inc.
Harmony Biosciences announced a leadership transition where CEO Jeffrey M. Dayno will retire on December 31, 2026, and current COO Peter Anastasiou will succeed him as President, CEO, and board member effective January 1, 2027. The company reaffirmed its full-year 2026 WAKIX net revenue guidance of $1.0 billion to $1.04 billion and remains committed to its existing strategic priorities.…more
$36.02-0.25%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.18After-hours26.09.19 05:484Ownership
Harmony Biosciences Holdings, Inc.
Insider Budur Kumar of Harmony Biosciences Holdings, Inc. reported changes in beneficial ownership of securities as of September 16, 2026. This filing serves as a standard disclosure regarding the insider's equity holdings.…more
$36.02-0.25%vs prev closeView filingShare - 9.18After-hours26.09.19 05:19144Ownership
Harmony Biosciences Holdings, Inc.
Harmony Biosciences Holdings insider Budur Kumar has filed a Form 144 to report a proposed sale of company shares. This is a standard regulatory filing disclosing an insider's plan to dispose of their holdings.…more
$36.02-0.25%vs prev closeView filingShare
13 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 4d agoPre-market26.10.20 21:05#●●●#●●●
Harmony Biosciences to Report Q3 2026 Financial Results on Nov 4
Harmony Biosciences announced that it will release its third-quarter 2026 financial results before the market opens on November 4, 2026. The company will also host a conference call to discuss the quarterly performance.…more
$36.02-0.25%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.12Pre-market26.10.12 20:00
●●●●●●●● ●●●●● ●●●●●●
Harmony Biosciences announced that current COO Peter Anastasiou will succeed Dr. Jeffrey Dayno as CEO, effective January 1, 2027. The company reiterated its 2026 revenue guidance and remains committed to its existing strategic pipeline priorities.…more
$36.02-0.25%vs prev close - 10.1Pre-market26.10.01 21:05
●●●●●●●● ●●●●● ●●●●●●
Harmony Biosciences will present poster data from its ongoing Phase 3 trials of HBS-301 for narcolepsy and idiopathic hypersomnia at the 17th European Narcolepsy Days. This academic presentation provides an update on clinical progress but does not constitute a material financial event.…more
$36.02-0.25%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report